Escitalopram in Schizophrenia in OCD- Open Label Study - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

December 3, 2006

Last Updated Date

January 26, 2009

Start Date ^†

July 2006

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00456937 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Escitalopram in Schizophrenia in OCD- Open Label Study

Official Title ^†

Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study

Brief Summary

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Detailed Description

Study Phase

Phase IV

Study Type ^†

Interventional

Study Design ^†

Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Condition ^†

Schizophrenia

Intervention ^†

Drug: Escitalopram

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Estimated Enrollment ^†

Completion Date

September 2008

Primary Completion Date

September 2008 (final data collection date for primary outcome measure)

Eligibility Criteria ^†

Inclusion Criteria:

Patients who suffer from schizophrenia and OCD

Exclusion Criteria:

Substance abuse,
Serious medical condintions,
Being on SSRI treatment

Gender

Both

Ages

18 Years to 65 Years

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

Israel

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00456937

Responsible Party

Dr Rafael Stryjer, Beer-Yaakov MHC

Secondary IDs ^††

Study Sponsor ^†

BeerYaakov Mental Health Center

Collaborators ^††

Lundbeck Israel

Investigators ^†

Principal Investigator:

Rafael Octavio Stryjer, M.D.

Beer Yaakov Mental Health Center

Information Provided By

BeerYaakov Mental Health Center

Verification Date

January 2009

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.